Research on the treatment of advanced biliary tract cancer has focused on the combination of durvalumab with gemcitabine and cisplatin. Some studies, including the TOPAZ-1 trial, have reported on the effectiveness of this combination, with some outlets suggesting it may become a new standard of care. The treatment's benefits, including overall survival, have been explored in various trials and analyses, with some results indicating a potential advantage over other treatments.